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adjustment for age, gender, ethnicity, and surgical treatment. Among 
stage IV NSCLC cases, those with ipsilateral intrapulmonary metasta-
sis (n=1120) had improved OS (13m) compared to those with bilateral 
intrapulmonary metastasis (n=1890; OS=7m) (P < 0.0001) (Figure 2).
Conclusions: Among stage IIIB and IV NSCLC cases, those present-
ing with ipsilateral intrapulmonary metastasis have improved survival 
outcomes. Our results add further support for modiﬁcation to the cur-
rent non-small-cell lung cancer staging system.
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Purpose: To evaluate the usefulness of FDG-PET/CT (PET/CT), supe-
rior to CT, for determining tumor response to treatment after stereotac-
tic radiosurgery (SRS) in primary or metastatic lung cancer
Methods: Thirty-ﬁve patients, with lung tumor, treated with SRS 
between July 2004 and June 2006 were reviewed. Treatment aim was 
curative or salvage in 30 primary or recurrent lung cancer patients, 
palliative in 15 metastatic lung cancer patients. SRS delivered 36, 48, 
or 60 Gy radiation, 12 or 20 Gy per fraction, to gross tumor with 5mm 
margin for 3 or 4 days consecutively. PET/CT was checked twice for 
measuring changes of maximal standardized uptake value (SUVmax), 
1 or 2 months before and after SRS, and CT was checked coincidently. 
Evaluation of tumor response with PET/CT used a level of SUV 
change, and response criteria were divided into complete remission 
(CR; maximal SUV decrease ≥70%), partial remission (PR; 10-69% 
decrease), no response (NR; 10% decrease-10% increase), and disease 
progression (PD; >10% increase)
Results: SUVmax value in PET/CT before and after SRS were 
0.80-13.10 (median 5.3) and background uptake-7.20 (median 1.70) 
respectively. Decrease rate of SUVmax was (-25.0)-98.3% (median 
50.0%). Metabolic response judged by PET/CT was CR in 17 (37.8%), 
PR in 19 (42.2%), NR in 8 (17.8%), and PD in 1 (2.2%) patients. Clini-
cal response judged by CT was CR in 2 (4.4%), PR in 18 (45.0%), NR 
in 20 (44.5%), PD in 5 (11.1%) patients. Peritumoral radiation induced 
pneumonitis or ﬁbrosis was a confounding factor for evaluation with 
CT especially in PD or NR groups, but PET/CT could differentiate such 
inﬂammatory lesion with actual tumor progression in some patients.
Conclusion: PET/CT at 1 month after SRS could reﬂect actual re-
sponse better than CT examined coincidently. FDG-PET/CT at 1 month 
before and after SRS might be a useful modality for evaluation of 
tumor response after treatment
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Background: We showed that PCG signiﬁcantly increases both 
Response Rate (RR) (43.6% vs 20%) and median survival time (10.8 
mo vs 8.3 mo) over PC and that at Cox analysis, the only independent 
prognostic factors were PS and Treatment (Paccagnella et al, J Clin 
Oncol 2006;24: 681-687).
According to the Prentice criteria (Stat Med 1989;8: 431-440), to 
directly relate Response and Survival it is necessarily that Responding 
patients (and non Responding) for both arms have a similar survival 
and that the survival difference between the two arms disappear when 
the Response Factor is included in the Multivariate Analysis.
Methods: Out of 324 pts included in the original analysis, 26 pts not 
evaluable for response (early death, toxicity, refusal) before the planned 
response evaluation at two months were excluded (15 pts from PC arm 
and 11 pts from PCG arm). The analysis was however also performed 
considering the no evaluable patients as non responders.
Results: Overall, Responder patients had a median Survival that nearly 
doubled that of no Responders: 14.73 mo vs 7.67 mo (HR: 0.49; CI: 
0.31 - 0.54; P= 0.000). 
No Responders pts from PC and PCG arms had a similar survival (me-
dian 7.53 mo and 8.07 mo respectively; P= 0.96) as well as respond-
ers (CR + PR) patients (median 14.13 mo and 15.40 mo respectively; 
P=0.38).
The only difference between the two arms was that more than the 
double of patients in PCG arm responded (43.6% vs 20%) and conse-
